EGFR and non-small cell lung carcinoma: Given the importance of MCL-1 proteolysis for apoptosis priming, prompt destruction of MCL-1 as an immediate response to anti-cancer treatment therefore underlies sensitivity to Osimertinib in EGFR mutant NSCLC.